☆ 4.8 Article

Immune checkpoints expression patterns in early-stage triple-negative breast cancer predict prognosis and remodel the tumor immune microenvironment

FRONTIERS IN IMMUNOLOGY (2023)

Related references

Note: Only part of the references are listed.

Review Pathology

Pathogenesis of Triple-Negative Breast Cancer

Fatemeh Derakhshan et al.

Summary: This article introduces the heterogeneity of triple-negative breast cancer (TNBC) and discusses its histologic, molecular classifications, and genomic alterations. The article also explores the role of the tumor microenvironment in TNBC and its potential impact on therapeutic response. Understanding the biology of each TNBC subtype is essential for delivering personalized medicine to patients.

ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2022)

Add to Collection

Review Oncology

Treatment landscape of triple-negative breast cancer - expanded options, evolving needs

Giampaolo Bianchini et al.

Summary: Recent advances in omics technologies have improved our understanding of the heterogeneity and microenvironment of triple-negative breast cancers (TNBCs), supporting a view of this breast cancer subtype as an ecosystem that encompasses both intrinsic and extrinsic features of cancer cells. The authors of this Review describe the current and upcoming therapeutic landscape of TNBC and discuss how an integrated view of the TNBC ecosystem can provide improved opportunities for tailoring treatment.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

FGD3 binds with HSF4 to suppress p65 expression and inhibit pancreatic cancer progression

Feng Guo et al.

Summary: Pancreatic cancer is characterized by deregulated and constitutively activated NF-kappa B signaling. FGD3, which is downregulated in pancreatic cancer tissues, inhibits cancer cell proliferation, invasion, and metastasis by activating the NF-kappa B signaling pathway. These findings suggest a potential target for pancreatic cancer treatment.

ONCOGENE (2022)

Add to Collection

Article Cell Biology

Unraveling the Expression Patterns of Immune Checkpoints Identifies New Subtypes and Emerging Therapeutic Indicators in Lung Adenocarcinoma

Jinguo Zhang et al.

Summary: This study comprehensively evaluated the expression profiles of immune checkpoint genes (ICGs) in lung adenocarcinoma and linked them to immune cell infiltration, clinical features, and response to immunotherapy. Three distinct ICG expression patterns and three ICG-related genomic clusters were identified, which were associated with different clinical outcomes, immune infiltrates, and biological processes.

OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer

Maryam Nakhjavani et al.

Summary: Triple-negative breast cancer (TNBC) has the worst prognosis among breast cancer subtypes and lacks targeted therapy. Immunotherapy targeting PD-1/PD-L1 has shown promise. Aptamers, with their better tissue penetration and lower production cost compared to mAbs, present a potential pathway for PD-1/PD-L1 modulation in the future.

PHARMACOLOGICAL RESEARCH (2022)

Add to Collection

Article Oncology

Increased CD8+ T-cell Infiltration and Efficacy for Multikinase Inhibitors After PD-1 Blockade in Hepatocellular Carcinoma

Hiroto Kikuchi et al.

Summary: Immune checkpoint blockade combined with antiangiogenic therapy is effective for hepatocellular carcinoma (HCC), and initial immunotherapy can enhance the efficacy of subsequent antiangiogenic therapy.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial

Song-Yang Wu et al.

Summary: This study explores patient subpopulations that are more likely to benefit from immunotherapy in triple-negative breast cancer (TNBC) and identifies actionable targets for checkpoint blockade. It also demonstrates the clinical value of combining famitinib, camrelizumab, and chemotherapy in advanced immunomodulatory TNBC patients. CD8 and/or PD-L1 positive tumors are associated with better response to this combination regimen.

MOLECULAR CANCER (2022)

Add to Collection

Article Oncology

Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy

Shreyas Gaikwad et al.

Summary: Immune checkpoint proteins (ICPs) are currently a promising area of immune-oncology research, with ongoing clinical trials to develop immunotherapeutic agents. However, there are challenges such as adverse side effects and lack of response in certain populations. Understanding the expression pattern and cellular mechanism of ICPs is crucial for the safe and effective development of targeted immunotherapy.

SEMINARS IN CANCER BIOLOGY (2022)

Add to Collection

Article Genetics & Heredity

Dissecting the Role of Immune Checkpoint Regulation Patterns in Tumor Microenvironment and Prognosis of Gastric Cancer

Zili Zhen et al.

Summary: The study identified three distinct immune checkpoint regulation patterns in gastric cancer samples, which significantly impact patient prognosis. Patients can be divided into two subgroups based on immune checkpoint score (ICscore), with those having lower ICscore showing better prognosis and other advantageous characteristics.

FRONTIERS IN GENETICS (2022)

Add to Collection

Article Immunology

Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy

Tobias Hoch et al.

Summary: Intratumoral immune cells play a crucial role in tumor control and antitumor responses during immunotherapy. This study analyzed the chemokine expression and immune infiltration in melanoma using multiplexed mass cytometry-based imaging, and found that tumors lacking immune infiltration had low levels of chemokines, antigen presentation, and markers of inflammation, while infiltrated tumors expressed multiple chemokines.

SCIENCE IMMUNOLOGY (2022)

Add to Collection

Review Immunology

Stem cell like memory T cells: A new paradigm in cancer immunotherapy

Fengdi Wang et al.

Summary: Memory T stem cell (T-SCM) cells are considered the pinnacle of memory T cell differentiation due to their self-renewal and replenishing properties. Manipulations of cytokines, metabolic factors, signal pathways, and T cell receptor signal intensity have been proposed to induce more T-SCM cells, which could potentially provide long-lasting and effective anti-tumor effects in cancer immunotherapies. This review summarizes the differentiation characteristics of T-SCM cells and strategies to generate more T-SCM cells, with a focus on their roles and applications in adoptive cell transfer therapy and cancer therapeutic vaccines.

CLINICAL IMMUNOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling

Dario Zimmerli et al.

Summary: MYC plays a crucial role in suppressing anti-tumour immunity in triple-negative breast cancer by directly regulating the transcription of interferon signalling genes. MYC overexpression decreases lymphocyte infiltration in tumors and prevents the recruitment and activation of immune cells. These findings reveal the mechanisms by which MYC overexpression leads to poor immunogenicity in triple-negative breast cancer.

NATURE COMMUNICATIONS (2022)

Add to Collection

Review Oncology

Emerging treatment strategies for metastatic triple-negative breast cancer

Laura A. Huppert et al.

Summary: This review article discusses novel treatment strategies for metastatic triple-negative breast cancer (mTNBC), including immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates. The article summarizes important preclinical and clinical data, discusses implications for clinical practice, and highlights future research directions.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

Add to Collection

Article Cell Biology

Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

Yi-Zhou Jiang et al.

Summary: The FUTURE trial demonstrated the clinical benefit of subtyping-based targeted therapy for refractory metastatic TNBC, with immunotherapy showing the highest objective response rate among the treatment arms. Somatic mutations of TOP2A and CD8 immunohistochemical score may have the potential to predict immunotherapy response in the immunomodulatory subtype of TNBC.

CELL RESEARCH (2021)

Add to Collection

Article Biochemical Research Methods

Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response

Fei-Fei Hu et al.

Summary: The study identified expression patterns of ICGs and their correlations with patient response to immune checkpoint blockade therapy, providing insights into the mechanisms of ICGs in anticancer treatments. A model using ICG expression features showed robust performance in predicting patient responses and outperformed other mRNA-based predictors.

BRIEFINGS IN BIOINFORMATICS (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Endocrinology & Metabolism

Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Na Li et al.

Summary: This study established immune-related gene-prognostic models in LUAD and LUSC based on mRNAsi, showing a correlation between tumor stemness index and immune cell infiltration in lung cancer tissues.

FRONTIERS IN ENDOCRINOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

CSK-homologous kinase (CHK/MATK) is a potential colorectal cancer tumour suppressor gene epigenetically silenced by promoter methylation

Anderly C. Chueh et al.

Summary: The study reveals that downregulation of CHK/MATK expression in CRC cells is associated with promoter hypermethylation, leading to hyperactivation of SFKs and enhanced tumorigenic activity. Restoring CHK/MATK expression reduces SFK activity, inhibiting proliferation and migration of colorectal cancer cells in vitro and in vivo.

ONCOGENE (2021)

Add to Collection

Article Immunology

Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis

Chundi Gao et al.

Summary: In this study, it was found that TNBC patients in the high TMB group had a higher survival rate, with differences in immune cell infiltration between the two groups. The FAT3 gene plays an important role in TNBC, not only related to patient prognosis, but also affecting immune cell infiltration.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Cell Biology

Identification of a Tumor Microenvironment-Related Gene Signature Indicative of Disease Prognosis and Treatment Response in Colon Cancer

Wenzheng Chen et al.

Summary: In this study, a TME-related gene signature was constructed to predict disease survival and immunotherapy response in colon cancer. High immune and stromal scores were associated with poor overall survival, and nine key prognostic genes were identified for the signature. Overall, the gene signature could potentially improve outcomes and guide therapy for colon cancer patients.

OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2021)

Add to Collection

Article Genetics & Heredity

Methylation of TMEM176A, a key ERK signaling regulator, is a novel synthetic lethality marker of ATM inhibitors in human lung cancer

Hongxia Li et al.

Summary: The methylation of TMEM176A gene in human lung cancer can affect the sensitivity of cancer cells to treatment, and may serve as a diagnostic marker and therapeutic target for lung cancer.

EPIGENOMICS (2021)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Gene expression profiling identified TP53MutPIK3CAWild as a potential biomarker for patients with triple-negative breast cancer treated with immune checkpoint inhibitors

Jia'nan Cheng et al.

ONCOLOGY LETTERS (2020)

Add to Collection

Article Genetics & Heredity

Construction of an Immunogenomic Risk Score for Prognostication in Colon Cancer

Han Zhang et al.

FRONTIERS IN GENETICS (2020)

Add to Collection

Article Biochemistry & Molecular Biology

TIMER2.0 for analysis of tumor-infiltrating immune cells

Taiwen Li et al.

NUCLEIC ACIDS RESEARCH (2020)

Add to Collection

Article Oncology

Identification and validation of tumor microenvironment-related genes of prognostic value in lung adenocarcinoma

Jingyan Yuan et al.

ONCOLOGY LETTERS (2020)

Add to Collection

Article Oncology

Tumor mutation burden and JARID2 gene alteration are associated with short disease-free survival in locally advanced triple-negative breast cancer

Xiangmei Zhang et al.

ANNALS OF TRANSLATIONAL MEDICINE (2020)

Add to Collection

Article Oncology

Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis

Zhao-hua Gao et al.

BMC CANCER (2020)

Add to Collection

Article Oncology

Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies

Yi-Zhou Jiang et al.

CANCER CELL (2019)

Add to Collection

Article Oncology

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

F. Cardoso et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Multidisciplinary Sciences

Expression of FGD3 gene as prognostic factor in young breast cancer patients

Irene Renda et al.

SCIENTIFIC REPORTS (2019)

Add to Collection

Article Environmental Sciences

Prognostic Value of CD1B in Localised Prostate Cancer

Cheng-Hsueh Lee et al.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2019)

Add to Collection

Article Oncology

Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy

J. H. Park et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Oncology

Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function

Hye Ryun Kim et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Add to Collection

Article Oncology

The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)

Nobumoto Tomioka et al.

BREAST CANCER (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation

Tathiane M. Malta et al.

CELL (2018)

Add to Collection

Article Oncology

The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective

Helmy M. Guirgis

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

Add to Collection

Article Medicine, General & Internal

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

P. Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Epigenetic silencing of TMEM176A activates ERK signaling in human hepatocellular carcinoma

Hongxia Li et al.

CLINICAL EPIGENETICS (2018)

Add to Collection

Article Oncology

An assessment of prognostic immunity markers in breast cancer

Benlong Yang et al.

NPJ BREAST CANCER (2018)

Add to Collection

Article Cell Biology

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade

Pornpimol Charoentong et al.

CELL REPORTS (2017)

Add to Collection

Article Biochemistry & Molecular Biology

The prognostic landscape of genes and infiltrating immune cells across human cancers

Andrew J. Gentles et al.

NATURE MEDICINE (2015)

Add to Collection

Article Biochemical Research Methods

Robust enumeration of cell subsets from tissue expression profiles

Aaron M. Newman et al.

NATURE METHODS (2015)

Add to Collection

Article Multidisciplinary Sciences

pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels

Paul Geeleher et al.

PLOS ONE (2014)

Add to Collection

Article Biochemical Research Methods

GSVA: gene set variation analysis for microarray and RNA-Seq data

Sonja Haenzelmann et al.

BMC BIOINFORMATICS (2013)

Add to Collection

Article Oncology

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

Sherene Loi et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection

Article Multidisciplinary Sciences

Inferring tumour purity and stromal and immune cell admixture from expression data

Kosuke Yoshihara et al.

NATURE COMMUNICATIONS (2013)

Add to Collection

Article Cell Biology

Abnormal accumulation of human transmembrane (TMEM)-176A and 176B proteins is associated with cancer pathology

Math P. Cuajungco et al.

ACTA HISTOCHEMICA (2012)

Add to Collection

Article Multidisciplinary Sciences

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

Christina Curtis et al.

NATURE (2012)

Add to Collection

Article Biotechnology & Applied Microbiology

clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters

Guangchuang Yu et al.

OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2012)

Add to Collection

Article Biochemical Research Methods

ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking

Matthew D. Wilkerson et al.

BIOINFORMATICS (2010)

Add to Collection

Article Cell Biology

Novel insights into FGD3, a putative GEF for Cdc42, that undergoes SCFFWD1/β-TrCP-mediated proteasomal degradation analogous to that of its homologue FGD1 but regulates cell morphology and motility differently from FGD1

Makio Hayakawa et al.

GENES TO CELLS (2008)

Add to Collection

Review Immunology

Inhibitory B7-family molecules in the tumour microenvironment

Weiping Zou et al.

NATURE REVIEWS IMMUNOLOGY (2008)

Add to Collection

Article Hematology

Identification of the nonreceptor tyrosine kinase MATK/CHK as an essential regulator of immune cells using Matk/CHK-deficient mice

Byeong-Chel Lee et al.

BLOOD (2006)

Add to Collection

Article Immunology

Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies

Y Wang et al.

JOURNAL OF IMMUNOLOGY (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.